pubmed-article:20218875 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20218875 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:20218875 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
pubmed-article:20218875 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
pubmed-article:20218875 | lifeskim:mentions | umls-concept:C0040557 | lld:lifeskim |
pubmed-article:20218875 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
pubmed-article:20218875 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:20218875 | pubmed:dateCreated | 2010-3-17 | lld:pubmed |
pubmed-article:20218875 | pubmed:abstractText | Toxoplasmosis is an often fatal opportunistic infection following allogeneic hematopoietic stem cell transplantation and is largely due to deferred diagnosis. In addition, breakthrough infections occur during prophylaxis with trimethoprim-sulfamethoxazole. | lld:pubmed |
pubmed-article:20218875 | pubmed:language | eng | lld:pubmed |
pubmed-article:20218875 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20218875 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20218875 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20218875 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20218875 | pubmed:month | Apr | lld:pubmed |
pubmed-article:20218875 | pubmed:issn | 1537-6591 | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:DelforgeMiche... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:Van... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:VerhoefGregor... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:MaertensJohan... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:DevosTimothyT | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:TheunissenKoe... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:LagrouKatrien... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:MeerssemanWou... | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:JanssensAnnA | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:DierickxDaanD | lld:pubmed |
pubmed-article:20218875 | pubmed:author | pubmed-author:MeersStefS | lld:pubmed |
pubmed-article:20218875 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20218875 | pubmed:day | 15 | lld:pubmed |
pubmed-article:20218875 | pubmed:volume | 50 | lld:pubmed |
pubmed-article:20218875 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20218875 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20218875 | pubmed:pagination | 1127-34 | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:meshHeading | pubmed-meshheading:20218875... | lld:pubmed |
pubmed-article:20218875 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20218875 | pubmed:articleTitle | Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. | lld:pubmed |
pubmed-article:20218875 | pubmed:affiliation | Hematology Department, University Hospitals Leuven, 3000 Leuven, Belgium. stef_meers@hotmail.com | lld:pubmed |
pubmed-article:20218875 | pubmed:publicationType | Journal Article | lld:pubmed |